Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.29 USD | -1.42% | -2.61% | -.--% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 390M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials